Insider Selling: Surgery Partners (NASDAQ:SGRY) CEO Sells 11,462 Shares of Stock

Surgery Partners, Inc. (NASDAQ:SGRY) CEO Jason Eric Evans sold 11,462 shares of Surgery Partners stock in a transaction that occurred on Friday, March 6th. The shares were sold at an average price of $13.79, for a total transaction of $158,060.98. Following the sale, the chief executive officer owned 662,680 shares in the company, valued at approximately $9,138,357.20. The trade was a 1.70% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Surgery Partners Price Performance

NASDAQ:SGRY traded down $0.06 during trading hours on Monday, reaching $13.30. The stock had a trading volume of 1,453,571 shares, compared to its average volume of 1,733,344. The stock has a market capitalization of $1.72 billion, a PE ratio of -21.45 and a beta of 1.95. The company has a 50 day moving average price of $15.16 and a two-hundred day moving average price of $18.00. The company has a debt-to-equity ratio of 1.15, a quick ratio of 1.71 and a current ratio of 1.87. Surgery Partners, Inc. has a 52 week low of $12.25 and a 52 week high of $24.60.

Surgery Partners (NASDAQ:SGRY) last issued its quarterly earnings data on Monday, March 2nd. The company reported $0.12 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.19). The company had revenue of $885.00 million for the quarter, compared to analysts’ expectations of $866.54 million. Surgery Partners had a negative net margin of 2.35% and a positive return on equity of 1.28%. The company’s revenue for the quarter was up 2.4% on a year-over-year basis. During the same quarter last year, the company earned $0.44 earnings per share. As a group, sell-side analysts anticipate that Surgery Partners, Inc. will post 0.67 earnings per share for the current fiscal year.

Surgery Partners declared that its Board of Directors has approved a share buyback program on Thursday, February 26th that authorizes the company to repurchase $200.00 million in outstanding shares. This repurchase authorization authorizes the company to repurchase up to 9.7% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s board of directors believes its shares are undervalued.

Institutional Investors Weigh In On Surgery Partners

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. State of Wisconsin Investment Board raised its holdings in Surgery Partners by 0.4% in the 4th quarter. State of Wisconsin Investment Board now owns 151,504 shares of the company’s stock valued at $2,341,000 after buying an additional 668 shares during the period. ProShare Advisors LLC grew its holdings in shares of Surgery Partners by 6.9% in the fourth quarter. ProShare Advisors LLC now owns 14,135 shares of the company’s stock valued at $218,000 after purchasing an additional 909 shares in the last quarter. Jones Financial Companies Lllp grew its stake in shares of Surgery Partners by 313.1% in the third quarter. Jones Financial Companies Lllp now owns 1,227 shares of the company’s stock worth $27,000 after acquiring an additional 930 shares in the last quarter. California State Teachers Retirement System raised its position in Surgery Partners by 1.6% in the 2nd quarter. California State Teachers Retirement System now owns 65,091 shares of the company’s stock valued at $1,447,000 after purchasing an additional 1,021 shares in the last quarter. Finally, Police & Firemen s Retirement System of New Jersey raised its holdings in Surgery Partners by 7.2% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 17,582 shares of the company’s stock valued at $391,000 after acquiring an additional 1,176 shares in the last quarter.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Surgery Partners in a report on Wednesday, March 4th. Mizuho decreased their price target on shares of Surgery Partners from $19.00 to $17.00 and set an “outperform” rating for the company in a report on Thursday. Benchmark reaffirmed a “buy” rating on shares of Surgery Partners in a report on Tuesday, March 3rd. Royal Bank Of Canada cut their target price on shares of Surgery Partners from $31.00 to $20.00 and set an “outperform” rating for the company in a report on Wednesday, March 4th. Finally, Barclays lowered their price target on Surgery Partners from $18.00 to $14.00 and set an “equal weight” rating on the stock in a research report on Tuesday, March 3rd. Nine analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $24.45.

Key Surgery Partners News

Here are the key news stories impacting Surgery Partners this week:

• Positive Sentiment: Broker consensus: Several brokerages give SGRY an average recommendation of “Moderate Buy,” which can support demand and sentiment among growth/healthcare investors. Brokerage Recommendation
• Positive Sentiment: Investor conference: Surgery Partners will present at the Barclays 28th Annual Global Healthcare Conference (Mar 10), offering management a chance to reiterate guidance, margin plans and strategy — a potential catalyst if commentary is constructive. Conference Announcement
• Neutral Sentiment: Q4 highlights coverage: Industry write-ups summarizing outpatient and specialty care Q4 results include Surgery Partners; these summaries provide context on revenue and margin trends but add no single new catalyst. Q4 Coverage
• Neutral Sentiment: Analyst views mixed: Some outlets note mixed analyst opinions — supportive ratings exist but others highlight execution and margin risk; inconsistent analyst messaging can limit strong directional moves. Analysts Mixed
• Negative Sentiment: Shareholder fraud probe: Law firm Levi & Korsinsky has opened an investigation into potential securities law violations tied to past management statements about margin expansion — this raises legal/settlement risk and investor uncertainty. Fraud Investigation
• Negative Sentiment: Heavy insider selling: Multiple insiders — including the CEO (Jason Evans), CFO (David Doherty) and several other officers — sold shares the week of Mar 5–6 (large blocks at ~$13.60–$13.93). Concentrated insider disposals can be perceived negatively by the market; representative SEC filings available. SEC Filing (CEO Sale)

About Surgery Partners

Surgery Partners, Inc operates as a healthcare services provider specializing in the management and ownership of ambulatory surgery centers, surgical hospitals and multispecialty rehabilitation hospitals across the United States. Through its network of facilities, the company coordinates and delivers a broad range of outpatient surgical procedures in specialties such as orthopedics, ophthalmology, otolaryngology, gastroenterology, pain management and general surgery. Its integrated platform offers ancillary services including on-site imaging, laboratory testing, infusion therapy and physical, occupational and speech rehabilitation.

Since its establishment in 2010 and subsequent public listing in 2015, Surgery Partners has focused on strategic partnerships with physicians and health systems to expand access to cost-effective outpatient care.